182 related articles for article (PubMed ID: 22046342)
1. The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.
Royds JA; Al Nadaf S; Wiles AK; Chen YJ; Ahn A; Shaw A; Bowie S; Lam F; Baguley BC; Braithwaite AW; MacFarlane MR; Hung NA; Slatter TL
PLoS One; 2011; 6(10):e26737. PubMed ID: 22046342
[TBL] [Abstract][Full Text] [Related]
2. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
3. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.
McDonald KL; McDonnell J; Muntoni A; Henson JD; Hegi ME; von Deimling A; Wheeler HR; Cook RJ; Biggs MT; Little NS; Robinson BG; Reddel RR; Royds JA
J Neuropathol Exp Neurol; 2010 Jul; 69(7):729-36. PubMed ID: 20535033
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S
Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205
[TBL] [Abstract][Full Text] [Related]
5. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
[TBL] [Abstract][Full Text] [Related]
6. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
8. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis of Clinical Relevance via Telomere Maintenance Mechanism.
Sung JY; Cheong JH
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681758
[TBL] [Abstract][Full Text] [Related]
11. Cystic glioblastoma: an evaluation of IDH1 status and prognosis.
Sarmiento JM; Nuño M; Ortega A; Mukherjee D; Fan X; Black KL; Patil CG
Neurosurgery; 2014 Jan; 74(1):71-5: discussion 75-6. PubMed ID: 24089051
[TBL] [Abstract][Full Text] [Related]
12. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
13. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mosrati MA; Malmström A; Lysiak M; Krysztofiak A; Hallbeck M; Milos P; Hallbeck AL; Bratthäll C; Strandéus M; Stenmark-Askmalm M; Söderkvist P
Oncotarget; 2015 Jun; 6(18):16663-73. PubMed ID: 26143636
[TBL] [Abstract][Full Text] [Related]
15. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme.
Hakin-Smith V; Jellinek DA; Levy D; Carroll T; Teo M; Timperley WR; McKay MJ; Reddel RR; Royds JA
Lancet; 2003 Mar; 361(9360):836-8. PubMed ID: 12642053
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.
Kraus JA; Glesmann N; Beck M; Krex D; Klockgether T; Schackert G; Schlegel U
J Neurooncol; 2000 Jun; 48(2):89-94. PubMed ID: 11083071
[TBL] [Abstract][Full Text] [Related]
17. Potential clinical role of telomere length in human glioblastoma.
La Torre D; Aguennouz M; Conti A; Giusa M; Raffa G; Abbritti RV; Germano' A; Angileri FF
Transl Med UniSa; 2011 Sep; 1():243-70. PubMed ID: 23905037
[TBL] [Abstract][Full Text] [Related]
18. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
19. Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma.
Hung NA; Eiholzer RA; Kirs S; Zhou J; Ward-Hartstonge K; Wiles AK; Frampton CM; Taha A; Royds JA; Slatter TL
Mod Pathol; 2016 Mar; 29(3):212-26. PubMed ID: 26769142
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1
Kondo N; Barth RF; Miyatake SI; Kawabata S; Suzuki M; Ono K; Lehman NL
J Neurooncol; 2017 May; 133(1):107-118. PubMed ID: 28534152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
